News
People with COPD are vulnerable to small increases in PM2.5, with each 1 μg/m3 rise in long-term exposure linked to a 3.8% ...
3d
MedPage Today on MSNPulmonary Rehabilitation for COPD Pushes ForwardHome-based pulmonary rehabilitation has been slowly gaining momentum for chronic obstructive pulmonary disease (COPD), but ...
Canadian wildfire smoke has entered the Upper Midwest and poses significant health impacts in the hardest-hit areas.
3don MSN
Walking is a fundamental activity for maintaining health. While numerous studies have assessed how much people with chronic ...
Yet thanks to a new hospital-based educational and advocacy initiative for COPD patients, Croswell has been managing well at ...
Topline results were announced from two phase 3 trials evaluating itepekimab in former smokers with inadequately controlled COPD.
6d
Pharmaceutical Technology on MSNSanofi and Regeneron report results from two Phase III trials of COPD treatmentSanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results